APM
NBIX icon

Avidity Partners Management’s Neurocrine Biosciences NBIX Stock Holding History

Avidity Partners Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-85,700
Closed -$9.48M – 77
2025
Q1 		$9.48M Sell
85,700
-134,700
-61% -$17.1M 1.81% 18
2024
Q4 		$30.1M Sell
220,400
-239,600
-52% -$29.6M 2.95% 9
2024
Q3 		$53M Sell
460,000
-31,000
-6% -$4.25M 2.7% 7
2024
Q2 		$67.6M Sell
491,000
-45,500
-8% -$6.24M 2.87% 8
2024
Q1 		$74M Sell
536,500
-121,500
-18% -$16.6M 2.39% 8
2023
Q4 		$86.7M Buy
658,000
+5,900
+0.9% +$679K 3.16% 6
2023
Q3 		$73.4M Sell
652,100
-13,216
-2% -$1.39M 2.95% 4
2023
Q2 		$62.7M Sell
665,316
-150,384
-18% -$14.7M 2.19% 12
2023
Q1 		$82.6M Sell
815,700
-964,300
-54% -$100M 2.74% 12
2022
Q4 		$213M Sell
1,780,000
-75,700
-4% -$8.87M 4.61% 4
2022
Q3 		$197M Buy
1,855,700
+388,100
+26% +$39.4M 4.01% 4
2022
Q2 		$143M Buy
1,467,600
+307,600
+27% +$28.4M 3.28% 11
2022
Q1 		$109M Sell
1,160,000
-100,000
-8% -$8.47M 2.26% 17
2021
Q4 		$107M Buy
1,260,000
+411,100
+48% +$37.8M 2.28% 15
2021
Q3 		$81.4M Buy
848,900
+167,900
+25% +$15.9M 1.8% 16
2021
Q2 		$66.3M Buy
681,000
+159,600
+31% +$15.3M 1.79% 16
2021
Q1 		$50.7M Buy
521,400
+221,400
+74% +$23.2M 1.4% 26
2020
Q4 		$28.8M Buy
+300,000
New +$29M 0.93% 39
2020
Q3 		– Sell
-185,100
Closed -$22.6M – 80
2020
Q2 		$22.6M Buy
185,100
+87,100
+89% +$9.63M 1.45% 25
2020
Q1 		$8.48M Buy
98,000
+65,000
+197% +$6.36M 1.17% 31
2019
Q4 		$3.55M Buy
+33,000
New +$3.46M 2.24% 24

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Avidity Partners Management's NBIX Position: Q2 2025 in Review

Avidity Partners Management sold out of Neurocrine Biosciences (NBIX) in Q2 2025, closing a stake of 85,700 shares — an estimated $9.48M sold.

Avidity Partners Management first reported a position in NBIX in Q4 2019 and held it in 21 quarters. The position peaked at $213M in Q4 2022. 586 funds tracked by Wall St. Rank hold NBIX as of Q2 2025.

  • Avidity Partners Management reported no remaining Neurocrine Biosciences position as of Q2 2025 after selling out during the quarter.
  • Avidity Partners Management sold 85,700 Neurocrine Biosciences shares in Q2 2025, an estimated $9.48M.
  • Avidity Partners Management first reported a position in Neurocrine Biosciences in Q4 2019 and held it in 21 quarters.
  • Avidity Partners Management's Neurocrine Biosciences position peaked at $213M in Q4 2022.
  • 586 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2025.

Based on Avidity Partners Management's 13F filing for Q2 2025, filed 14 Aug 2025.